Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get all the relevant market information you need — get it fast, on time, and accurately with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

An2 Therapeutics Inc (ANTX)

An2 Therapeutics Inc (ANTX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 29,183
  • Shares Outstanding, K 27,402
  • Annual Sales, $ 0 K
  • Annual Income, $ -51,320 K
  • EBIT $ -37 M
  • EBITDA $ -41 M
  • 60-Month Beta -0.02
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 0.48

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -0.24
  • Number of Estimates 1
  • High Estimate -0.24
  • Low Estimate -0.24
  • Prior Year -0.25
  • Growth Rate Est. (year over year) +4.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.0100 +3.96%
on 11/28/25
1.2600 -16.67%
on 11/10/25
-0.0906 (-7.94%)
since 11/05/25
3-Month
1.0100 +3.96%
on 11/28/25
1.4200 -26.06%
on 09/18/25
-0.2100 (-16.67%)
since 09/05/25
52-Week
1.0100 +3.96%
on 11/28/25
1.5900 -33.96%
on 12/11/24
-0.4000 (-27.59%)
since 12/05/24

Most Recent Stories

More News
AN2 Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business and Scientific Highlights

Advancing Phase 1 program in Chagas Disease; Phase 2 planning underway Clinical-stage M. abscessus program advancing through investigator-initiated trial (IIT) ...

ANTX : 1.0500 (-1.41%)
AN2 Therapeutics Announces Research Collaboration With GSK to Advance Boron-Based LeuRS-Inhibitors Targeting Tuberculosis (TB)

AN2 awarded third year of funding from Gates Foundation

ANTX : 1.0500 (-1.41%)
AN2 Therapeutics to Participate in Fireside Chat at Evercore HealthCONx Conference

AN2 Therapeutics, Inc. (Nasdaq: ANTX), a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform, today announced that...

ANTX : 1.0500 (-1.41%)
AN2 Therapeutics Reports Second Quarter 2025 Financial Results and Recent Business and Scientific Highlights

Cash, cash equivalents, and investments of $71.2 million at June 30,2025 and cash runway anticipated to fund operations into 2028

ANTX : 1.0500 (-1.41%)
AN2 Therapeutics Commences First-in-Human Clinical Trial of Oral AN2-502998 for Chagas Disease

Preclinical studies in nonhuman primates naturally infected with T. cruzi have shown AN2-502998's curative potential in chronic Chagas disease ...

ANTX : 1.0500 (-1.41%)
AN2 Therapeutics and DNDi Collaborate on Clinical Development of Promising New Oral Compound to Treat Chronic Chagas Disease

DNDi to share extensive clinical trial network and expertise to rapidly advance the clinical development of AN2’s oral drug candidate AN2-502998, which...

ANTX : 1.0500 (-1.41%)
Insider Purchase: Director at $ANTX (ANTX) Buys 25,000 Shares

Robin Shane Readnour, a director at $ANTX ($ANTX), bought 25,000 shares of the company on 11-27-2024. This trade was reported by Quiver Quantitative using data from a recent SEC filing. This increased...

ANTX : 1.0500 (-1.41%)
Insider Purchase: Director at $ANTX (ANTX) Buys 5,000 Shares

Joseph S Zakrzewski, a director at $ANTX ($ANTX), bought 5,000 shares of the company on 11-19-2024. This trade was reported by Quiver Quantitative using data from a recent SEC filing. This increased their...

ANTX : 1.0500 (-1.41%)
The Five Biotech Stocks Every Investor Should Know About

Avalon GloboCare Corp., (NASDAQ: ALBT) a developer of innovative precision diagnostics and provider of clinical laboratory services just announced that the United States Patent and Trademark Office (USPTO)...

ALBT : 1.5000 (+2.74%)
INSM : 205.80 (+0.37%)
VIR : 6.51 (-3.98%)
CODX : 0.3702 (-4.22%)
ANTX : 1.0500 (-1.41%)
A Potentially Revolutionary Tuberculosis Test Can Produce Results in 24 Hours

With a rising prevalence of chronic diseases, we’re starting to see higher demand for clinical lab services. That being said, it’s no surprise that, according to Market.Us, the global market for clinical...

ALBT : 1.5000 (+2.74%)
INSM : 205.80 (+0.37%)
VIR : 6.51 (-3.98%)
CODX : 0.3702 (-4.22%)
ANTX : 1.0500 (-1.41%)

Business Summary

AN2 Therapeutics Inc. is a clinical-stage biopharmaceutical company. It focused on developing treatments for rare, chronic and serious infectious diseases with high unmet needs. AN2 Therapeutics Inc. is based in MENLO PARK, Calif.

See More

Key Turning Points

3rd Resistance Point 1.1667
2nd Resistance Point 1.1383
1st Resistance Point 1.1017
Last Price 1.0500
1st Support Level 1.0367
2nd Support Level 1.0083
3rd Support Level 0.9717

See More

52-Week High 1.5900
Fibonacci 61.8% 1.3684
Fibonacci 50% 1.3000
Fibonacci 38.2% 1.2316
Last Price 1.0500
52-Week Low 1.0100

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar